A Study Assessing Eloralintide (LY3841136) in Healthy Participants

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT07935304
StatusNot yet recruiting
PhasePhase 1
SponsorEli Lilly and Company
Enrollment90 participants
DesignInterventional, Randomized, Parallel, Masking: None
ConditionsHealthy
InterventionsEloralintide; Eloralintide
StartNov 2026
Primary completionApr 2027
Study completionApr 2027
Results postedNot yet
Registry last updatedNov 13, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

The main purpose of this study is to investigate the effects of where Eloralintide is subcutaneously (SC) injected into the body and to investigate how the body processes an intravenous (IV) dose of Eloralintide. Blood tests will be performed to investigate how the study drug affects the body. For each participant, the study will last about 12 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 6 nights.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Pharmacokinetics (PK): Area Under the Plasma Concentration Curve (AUC) of LY3841136 Administered Subcutaneously (SC)Baseline through Day 57
PK: Maximum Observed Drug Concentration (Cmax) of LY3841136 Administered SCBaseline through Day 57

2 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail